Cargando…

Complete remission of aggressive Epstein–Barr virus‐positive diffuse large B‐cell lymphoma following withdrawal of tacrolimus and low‐dose anticancer drugs

A 66‐year‐old woman who had received tacrolimus for more than 11 years was admitted with high fever, generalized lymphadenopathy, and persistent gastrointestinal bleeding. Histopathological evaluation of the lymph nodes and colonic mucosa confirmed the diagnosis of Epstein–Barr virus‐positive diffus...

Descripción completa

Detalles Bibliográficos
Autores principales: Obama, Kosuke, Yamamoto, Hana, Inoue, Hirosaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660111/
https://www.ncbi.nlm.nih.gov/pubmed/38024598
http://dx.doi.org/10.1002/jha2.761
Descripción
Sumario:A 66‐year‐old woman who had received tacrolimus for more than 11 years was admitted with high fever, generalized lymphadenopathy, and persistent gastrointestinal bleeding. Histopathological evaluation of the lymph nodes and colonic mucosa confirmed the diagnosis of Epstein–Barr virus‐positive diffuse large B‐cell lymphoma. After discontinuation of tacrolimus, the lymphoma did not improve, and low‐dose chemotherapy was introduced, which resulted in a recovery of lymphocyte counts and induction of complete remission. Low‐dose anticancer treatments that suppress tumor growth while awaiting normal lymphocyte recovery for several weeks may be a useful therapeutic option even for aggressive lymphomas that develop during immunosuppressant therapy.